Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa dose-escalation study of oral HPP737 in moderate to severe COPD
ChiCTR2100051725Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of HPP737 in chronic obstructive pulmonary disease (COPD) (5 arms), sponsored by West China Hospital of Sichuan University. Primary endpoints: Lung function test, Safety assessment and 2 more. Planned start Oct 2021; status: not yet recruiting.
02
Drugs
HPP737
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on ChiCTR2100051725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100051725.